SR proteins are misregulated in multiple cancers, and pharmacological targeting of the SRPK1‐SR axis has been proposed as a potential therapeutic approach (Amin et al, 2011; Mavrou et al, 2015; Mavrou & Oltean, 2016). This evidence concerns the gene SRPK1 and cancer.